MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	9/13/2007 4:47:37 AM
	Read Replies (1) of 2240

September 13, 09:31 AM Genmab sees further HuMax-Inflam clinical studies after deal with Medarex COPENHAGEN (Thomson Financial) - Genmab AS said an agreement with Medarex Inc to exchange rights to drug development assets will allow the Danish group to move its HuMax antibody into further clinical studies. Under the terms of the agreement, Genmab (Copenhagen: GEN.CO - news) will receive full rights to HuMax-Inflam/MDX-018, a human antibody being developed to treat inflammatory conditions, while Medarex (NASDAQ: MEDX - news) will receive full rights to Genmab's multiple disease programmes in oncology. Genmab and Medarex will release to each other all previously held economic interests in the assets exchanged. 'Genmab will now hold all the rights to the HuMax-Inflam antibody which we have developed in cooperation with Medarex and hope to move the product into further clinical studies soon,' said Lisa N Drakeman, Genmab's chief executive officer...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next